[Naso-subcutaneous application of the polycomponent vaccine VP-4 for the treatment of patients with bronchial asthma and chronic obstructive bronchitis].
Bacterial polycomponent vaccine (VP-4) earlier developed at the Mechnikov Research Institute for Vaccines and Sera on the basis of antigenic complexes of Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli, Staphylococcus aureus was used within the program of clinical trials, for the treatment of 30 patients aged 16-59 years with the atopic and mixed form of bronchial asthma and chronic obstructive bronchitis by the combined naso-subcutaneous application. A good therapeutic effect produced by the vaccine was registered in 83.3% of the patients. It was manifested by a lower frequency of acute respiratory diseases and bronchopulmonary diseases as well as decreased need in antibiotic therapy. In the group of comparison a good effect was noted in 40% of the patients during 6 months of observation (statistically significant difference). Side effects caused by the administration of the vaccine were transitory, had mainly local character and disappeared without any treatment. In 1 patient the development of anaphylactic shock was observed. The positive effect of vaccine VP-4 could be attributed to the improved indices of cell-mediated immunity, an increased synthesis of alpha- and gamma-interferon, a droped level of IgE and specific IgG antibodies to Staphylococcus sp., Klebsiella sp., Proteus sp., Escherichia coli.
Antonova
L P
LP
Markova
T P
TP
Kurbatova
E A
EA
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000707:Anaphylaxis / Q000209:etiology; D000907:Antibodies, Bacterial / Q000097:blood; D000918:Antibody Specificity; D000942:Antigens, Bacterial / Q000276:immunology; D001249:Asthma / Q000097:blood / Q000628:therapy*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D029481:Bronchitis, Chronic / Q000097:blood / Q000628:therapy*; D004334:Drug Administration Schedule; D004926:Escherichia coli / Q000276:immunology; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000097:blood; D007371:Interferon-gamma / Q000097:blood; D007711:Klebsiella pneumoniae / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011514:Proteus vulgaris / Q000276:immunology; D013211:Staphylococcus aureus / Q000276:immunology; D017778:Vaccines, Combined / Q000009:adverse effects / Q000627:therapeutic use
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D016898:Interferon-alpha; C088865:VP-4 vaccine; D017778:Vaccines, Combined; D007371:Interferon-gamma